Login

Journal Image
Recent Patents on Drug Delivery & Formulation
ISSN (Print): 1872-2113
ISSN (Online): 2212-4039
VOLUME: 8
ISSUE: 1
DOI: 10.2174/18722113113079990014









The Study of Marketed and Experimental Formulation Approaches Enabling Site-specific Delivery of Mesalamine in Patients with Inflammatory Bowel Disease

img
Author(s): Irina Kadiyala and Dylan Jacobs
Pages 3-11 (9)
Abstract:
This patent review focuses exclusively on the oral delivery of mesalamine (5-ASA) and excludes oral mesalamine pro-drug and rectal delivery formulations. The formulation strategies of marketed formulations (Apriso®, Asacol®, Lialda® and Pentasa®) and non-marketed formulations are reviewed and explained by decoding formulation specifics that enable the site specific delivery for the treatment of inflammatory bowel disease.
Keywords:
Apriso, asacol, asacol HD, 5-ASA, Crohn’s disease and ulcerative colitis, inflammatory bowel disease, lialda, mesalamine, oral delivery, pentasa.
Affiliation:
Vertex Pharmaceuticals Incorporated, Department of Formulation Development, 130 Waverly St., Cambridge, MA 02139-4242.